^
BIOMARKER:

KRAS G13D

i
Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Entrez ID:
Related biomarkers:
KRAS G13D
CRC
panitumumab
Resistant: A2 - Guideline
KRAS G13D
CRC
cetuximab
Resistant: A2 - Guideline
KRAS G13D
HCC
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
KRAS G13D
NSCLC
erlotinib
Resistant: C3 – Early Trials
KRAS G13D
CRC
RGX-202
Sensitive: C3 – Early Trials
KRAS G13D
CRC
bevacizumab + PCM-075
Sensitive: C3 – Early Trials
KRAS G13D
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
KRAS G13D
CRC
LY3214996
Sensitive: D – Preclinical
KRAS G13D
Colon Cancer
cetuximab
Resistant: D – Preclinical
KRAS G13D
CRC
MEN1611
Sensitive: D – Preclinical
KRAS G13D
CRC
BMS-754807
Resistant: D – Preclinical
KRAS G13D
CRC
cetuximab + vemurafenib
Resistant: D – Preclinical
KRAS G13D
CRC
sunitinib
Resistant: D – Preclinical
KRAS G13D
CRC
trametinib + TPX-0005
Sensitive: D – Preclinical
KRAS G13D
CRC
P1446A-05
Sensitive: D – Preclinical
KRAS G13D
Solid Tumor
MRTX849
Sensitive: D – Preclinical
KRAS G13D
Solid Tumor
sotorasib
Resistant: D – Preclinical
KRAS G13D
Pancreatic Adenocarcinoma
ASN007
Sensitive: D – Preclinical
KRAS G13D
Colorectal Adenocarcinoma
ASN007
Sensitive: D – Preclinical